Comparative Pharmacology
Head-to-head clinical analysis: LUVOX versus PAXIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUVOX versus PAXIL.
LUVOX vs PAXIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); increases serotonergic activity by blocking reuptake of serotonin into presynaptic neurons.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin (5-HT) from the synaptic cleft, leading to increased serotonin levels.
Initial dose 50 mg orally once daily at bedtime, titrated by 50 mg increments every 4-7 days to effective dose; usual therapeutic range 100-300 mg/day divided once daily (at bedtime) or twice daily if tolerated. Maximum dose 300 mg/day.
20 mg orally once daily, typically in the morning; may be increased in 10 mg/day increments at intervals of at least 1 week to a maximum of 50 mg/day.
None Documented
None Documented
Clinical Note
moderateFluvoxamine + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Fluvoxamine."
Clinical Note
moderateFluvoxamine + Desmopressin
"The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desmopressin."
Clinical Note
moderateFluvoxamine + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Fluvoxamine."
Clinical Note
moderateFluvoxamine + Clotrimazole
The terminal elimination half-life is approximately 15-20 hours but may be prolonged in patients with hepatic impairment or with advanced age. Steady-state is typically achieved within 7-10 days of chronic dosing.
Mean terminal half-life 21 hours (range 3–65 hours); steady-state achieved within 7–14 days; nonlinear kinetics with dose increase leading to disproportionate increases in half-life due to saturable hepatic metabolism (CYP2D6).
Approximately 94% of a dose is excreted in urine, mostly as conjugated and oxidized metabolites, with 2% as unchanged drug. Fecal excretion accounts for less than 4%.
Renal: 64% (2% unchanged, 62% as metabolites); Fecal: 36% via bile; urinary excretion of unchanged paroxetine <2%.
Category C
Category C
SSRI Antidepressant
SSRI Antidepressant
"The metabolism of Clotrimazole can be decreased when combined with Fluvoxamine."